Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

347
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
347
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.9K
Drug Therapy01:28

Drug Therapy

111
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
111
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

319
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
319
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

298
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
298
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

400
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
400

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Conversion from Major Depressive Disorder to Bipolar Disorder: A Population-Based PADRIS-PRESTO Cohort Study in Catalonia.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Pharmacological augmentation for people with treatment-resistant depression.

The British journal of psychiatry : the journal of mental science·2026
Same author

Olanzapine for young people with anorexia nervosa: a synopsis of the main results from the OPEN open-label feasibility study.

Health technology assessment (Winchester, England)·2026
Same author

The proportion of people with primary affective disorders presenting to early intervention services: systematic review and meta-analysis.

The British journal of psychiatry : the journal of mental science·2026
Same author

Mismatch negativity in patients with bipolar affective disorder: a systematic review and meta-analysis.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Regional Blood Flow Signatures of Opioidergic Modulation of Ketamine in Major Depressive Disorder: A Randomized Crossover Study.

The American journal of psychiatry·2026
Same journal

Functional neurological disorder in pregnancy, labour and the postpartum period: systematic review - CORRIGENDUM.

BJPsych bulletin·2026
Same journal

A nationwide mapping of services for high users of emergency departments in England: observational study.

BJPsych bulletin·2026
Same journal

Towards a feminist psychiatry.

BJPsych bulletin·2026
Same journal

Critical psychiatry in the UK: potentially useful but in need of regeneration.

BJPsych bulletin·2026
Same journal

Electroconvulsive treatment for schizophrenia: decade of national Scottish data.

BJPsych bulletin·2026
Same journal

People experiencing homelessness referred to general adult psychiatry teams in Dublin, Ireland.

BJPsych bulletin·2026
See all related articles

Related Experiment Video

Updated: Oct 3, 2025

Accessing Valuable Ligand Supports for Transition Metals: A Modified, Intermediate Scale Preparation of 1,2,3,4,5-Pentamethylcyclopentadiene
09:45

Accessing Valuable Ligand Supports for Transition Metals: A Modified, Intermediate Scale Preparation of 1,2,3,4,5-Pentamethylcyclopentadiene

Published on: March 20, 2017

10.6K

Plus ça change? Switching lithium preparations.

David A Cousins1,2, Thomas R E Barnes3,4, Allan H Young5,6

  • 1Newcastle University, Newcastle upon Tyne, UK.

Bjpsych Bulletin
|February 18, 2022
PubMed
Summary
This summary is machine-generated.

Switching lithium carbonate brands, like Priadel® to Camcolit®, showed similar plasma lithium levels in adherent patients. This suggests current guidance on switching lithium brands may be overly complex.

Keywords:
CamcolitPriadeladherenceplasma lithium levelsswitch

More Related Videos

1,3,5-Triphenylbenzene and Corannulene as Electron Receptors for Lithium Solvated Electron Solutions
06:56

1,3,5-Triphenylbenzene and Corannulene as Electron Receptors for Lithium Solvated Electron Solutions

Published on: October 10, 2016

7.9K
In Situ Neutron Powder Diffraction Using Custom-made Lithium-ion Batteries
11:25

In Situ Neutron Powder Diffraction Using Custom-made Lithium-ion Batteries

Published on: November 10, 2014

15.9K

Related Experiment Videos

Last Updated: Oct 3, 2025

Accessing Valuable Ligand Supports for Transition Metals: A Modified, Intermediate Scale Preparation of 1,2,3,4,5-Pentamethylcyclopentadiene
09:45

Accessing Valuable Ligand Supports for Transition Metals: A Modified, Intermediate Scale Preparation of 1,2,3,4,5-Pentamethylcyclopentadiene

Published on: March 20, 2017

10.6K
1,3,5-Triphenylbenzene and Corannulene as Electron Receptors for Lithium Solvated Electron Solutions
06:56

1,3,5-Triphenylbenzene and Corannulene as Electron Receptors for Lithium Solvated Electron Solutions

Published on: October 10, 2016

7.9K
In Situ Neutron Powder Diffraction Using Custom-made Lithium-ion Batteries
11:25

In Situ Neutron Powder Diffraction Using Custom-made Lithium-ion Batteries

Published on: November 10, 2014

15.9K

Area of Science:

  • Pharmacokinetics
  • Clinical Pharmacy
  • Drug Efficacy

Background:

  • A 2020 supply disruption alert prompted a switch from Priadel® (lithium carbonate) tablets.
  • Prescribers needed to understand the interchangeability of different lithium brands.

Purpose of the Study:

  • To evaluate lithium plasma levels and dosage before and after brand switching.
  • To determine the pharmacokinetic interchangeability of lithium carbonate brands.

Main Methods:

  • Service evaluation analyzing data from 37 patients.
  • Compared plasma lithium levels pre- and post-switch between brands.

Main Results:

  • Switching from Priadel® to Camcolit® at the same dose showed no significant plasma lithium level differences.
  • Dose adjustments and poor adherence correlated with higher plasma lithium variability.

Conclusions:

  • Common lithium carbonate brands yield similar plasma levels in adherent patients at comparable doses.
  • Current British National Formulary guidance for switching lithium brands may be unnecessarily complex.